February 11th, 2020 | 14:55 CET
Aphria, Canopy Growth, EXMceuticals - Europe becomes the largest cannabis market
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Cannabis has arrived in society
The cannabis boom of recent years is leading to changes in the legal system in more and more countries to provide medical and economic opportunities. The commercialization of a new product universe of different brands and unique selling points will continue to change the medical sector in the coming years.
More and more people accept cannabis as medical product and its use will become a part of modern society.
Internet as knowledge platform
The Internet as a media platform has driven the process of legalisation of cannabis for treatments. The experience of adults and children in dealing with medical cannabis could no longer be controlled by the conventional press and success stories spread virally in the social media.
Further education with first-hand information and the publication of scientific studies has allowed the process of decriminalisation to move forward. The number of opponents of legalisation in the USA fell from 52% in 2010 to just 32% in November 2019, according to the Pew Research Centre.
EXMceuticals with focus on Europe
The change of mind in society was supported by the use of CBD in trendy consumer goods, among other things. CBD can now be found in a variety of beverages and food products. In addition, this ingredient is also increasingly used in body care and beauty products. Antioxidants and the anti-inflammatory properties ensure that the products are becoming increasingly popular.
Investors who would like to participate in this development should take a closer look at the shares of Aphria, Canopy Growth and EXMceuticals. While the two giants Aphria and Canopy Growth have positioned themselves globally, EXMceuticals focuses on the European market from Portugal.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.